[{"id":"06ceeccc-7d55-46ab-9d6e-8f12f9fbc6ba","acronym":"PICASSO","url":"https://clinicaltrials.gov/study/NCT04988841","created_at":"2021-08-04T14:53:06.476Z","updated_at":"2024-07-02T16:35:35.795Z","phase":"Phase 2","brief_title":"Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma","source_id_and_acronym":"NCT04988841 - PICASSO","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" IL6 • ISG20","pipe":"","alterations":" ","tags":["IL6 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Xervyteg (MaaT013)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/20/2022","start_date":" 01/20/2022","primary_txt":" Primary completion: 01/20/2024","primary_completion_date":" 01/20/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-09-26"}]